Business
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR-001 and SKB105 on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026 with combination studies to follow CHENGDU, China and WALTHAM, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sichuan Kelun-Bio
About this update from Crescent Biopharma, Inc.
[{"type":"image","alt":"Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","displaySize":"","headline":null,"caption":"Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/26e5f5c519800f1bba8b99da2f3df5ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G8cbRsK80RDbmmGQ5j.tlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/26e5f5c519800f1bba8b99da2f3df5ab","width":300,"height":107}},"lazy":false},{"type":"text","content":"Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China","length":162,"tagName":"p"},{"type":"text","content":"Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105","length":130,"tagName":"p"},{"type":"text","content":"CR-001 and SKB105 on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026 with combination studies to follow","length":119,"tagName":"p"},{"type":"text","content":"CHENGDU, China and WALTHAM, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs, and Crescent Biopharma, Inc. (“Crescent”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the companies have entered into a strategic partnership to develop and commercialize oncology therapeutics, including novel combinations.","length":621,"tagName":"p"},{"type":"text","content":"The partnership involves Crescent’s CR-001, a PD-1 x VEGF bispecific antibody, and Kelun-Biotech’s SKB105, an integrin beta-6 (ITGB6)-directed antibody-drug conjugate (ADC) with a topoisomerase payload. Both candidates are being developed for the treatment of solid tumors and are expected to enter Phase 1/2 monotherapy clinical trials in the first quarter of 2026.","length":366,"tagName":"p"},{"type":"text","content":"Under the terms of the collaboration, Crescent has...